Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Upstream Bio, Inc. UPB NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$49.00
+396.5%

Upstream Bio, Inc. (UPB) is a Biotechnology company in the Healthcare sector, currently trading at $9.87. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is UPB = $49 (+396.5% upside).

Valuation: UPB trades at a trailing Price-to-Earnings (P/E) of -3.7 (S&P 500 average ~25).

Financials: revenue is $3M, +38.8%/yr average growth. Net income is $143M (loss), growing at -106.8%/yr. Net profit margin is -5026% (negative). Gross margin is 93.4% (-6.6 pp trend).

Balance sheet: total debt is $1M against $340M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 26.15 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $354M.

Analyst outlook: 0 / 1 analysts rate UPB as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 41/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$49.00
▲ 396.45% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for Upstream Bio, Inc., the average price target is $49.00, with a high forecast of $51.00, and a low forecast of $47.00.
Highest Price Target
$51.00
Average Price Target
$49.00
Lowest Price Target
$47.00

UPB SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — UPB

✓
VALUE Pass
100/100
UPB trades at a trailing Price-to-Earnings (P/E) of -3.7 (S&P 500 average ~25). Forward PEG -0.51 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.22. Analyst consensus target is $49, implying +396.5% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
UPB: +38.8%/yr revenue is, -106.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet UPB: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 26.15 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
UPB: Gross margin is 93.4% (-6.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 0 / 1 analysts rate UPB as buy (0%). Analyst consensus target is $49 (+396.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
UPB: Net profit margin is -5026%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.14-33.68
Volume540.51K
Avg Volume (30D)1.32M
Market Cap$537.13M
Beta (1Y)2.99
Share Statistics
EPS (TTM)-2.66
Shares Outstanding$53.85M
IPO Date2024-10-11
Employees52
CEOE. Rand Sutherland
Financial Highlights & Ratios
Revenue (TTM)$2.85M
Gross Profit$2.67M
EBITDA$-160.36M
Net Income$-143.44M
Operating Income$-160.36M
Total Cash$341.51M
Total Debt$1.27M
Net Debt$-100.31M
Total Assets$353.77M
Price / Earnings (P/E)-3.7
Price / Sales (P/S)188.2
Analyst Forecast
1Y Price Target$49.00
Target High$51.00
Target Low$47.00
Upside+396.5%
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS91678A1079

Price Chart

Track all markets on TradingView
UPB
Upstream Bio, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
5.14 52WK RANGE 33.68

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 SYRE
SYRE
Spyre Therapeutics, Inc.
$68.99
+7.78%
 RLAY
RLAY
Relay Therapeutics, Inc.
$15.49
+5.02%
 SNDX
SNDX
Syndax Pharmaceuticals, Inc.
$24.33
-0.41%
 PHVS
PHVS
Pharvaris N.V.
$29.14
+1.60%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.94
+1.08%
 WVE
WVE
Wave Life Sciences Ltd.
$7.59
+2.71%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$17.12
+1.18%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message